Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rigosertib 72-hour continuous intravenous infusion in higher-blast myelodysplastic syndrome after azacitidine or decitabine failure
2013-001124-19Phase 3Completed
- Sponsor
- Onconova Therapeutics, Inc.
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rigosertib in myelodysplastic syndrome (MDS), sponsored by Onconova Therapeutics, Inc. Primary endpoints: Overall survival and Best bone marrow blast response. Started May 2013; status: completed.
02
Drugs
rigosertib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2013-001124-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001124-19.